Immunotherapeutic effects of recombinant Bacillus Calmette–Guérin containing sic gene in ex vivo and in vivo bladder cancer models
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jung Hoon | - |
dc.contributor.author | Choi, Joongwon | - |
dc.contributor.author | Kim, Mirinae | - |
dc.contributor.author | Kang, Su Jeong | - |
dc.contributor.author | Choi, Young Wook | - |
dc.contributor.author | Choi, Se Young | - |
dc.contributor.author | Kim, Sung-Hwan | - |
dc.contributor.author | Chang, In Ho | - |
dc.date.accessioned | 2022-04-05T07:40:08Z | - |
dc.date.available | 2022-04-05T07:40:08Z | - |
dc.date.issued | 2022-03 | - |
dc.identifier.issn | 2466-0493 | - |
dc.identifier.issn | 2466-054X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/55803 | - |
dc.description.abstract | Purpose: The recombinant Bacillus Calmette–Guérin (BCG) containing the streptococcal inhibitor of the complement gene (rBCG-sic) may be more resistant to antimicrobial peptides and improve internalization; therefore, it can enhance the immunotherapeutic effect of the BCG. Here we determined the optimal dose of rBCG-sic and compared its effectiveness with that of BCG.Materials and Methods: We fabricated a high-throughput 3D-bioprinted bladder cancer-on-a-chip (BCOC) and used it to evaluate the effectiveness of the rBCG-sic in terms of cell viability, cell migration, and cytokine concentrations. Using an orthotopic mouse model, we evaluated its anticancer effect and toxicity via bioluminescence imaging.Results: T24 cell viability was decreased after treatment with rBCG-sic 30 multiplicities of infection (MOI) versus the same dosage of mock BCG (42.8%±6.4% vs. 75.7%±6.6%, p<0.05). THP-1 cell migration was positively correlated with rBCG-sic concentration (2.42-fold at 30MOI, p<0.01). The interleukin-6 concentration of rBCG-sic 30MOI was significantly higher than that of mock BCG 30MOI (11.2±1.3 pg/mL vs. 6.7±0.6 pg/mL, p<0.05). In the orthotopic bladder cancer mouse model, lower tumor volume was observed in the rBCG-sic 30MOI group than in the BCG 30MOI group after 10 days of treatment (p<0.05). Conclusions: We concluded that rBCG-sic is a useful tool for overcoming BCG unresponsiveness in non-muscle invasive bladder cancer. Additionally, high-throughput BCOC with a microfluidic system can successfully reflect the bladder cancer microenvironment. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한비뇨의학회 | - |
dc.title | Immunotherapeutic effects of recombinant Bacillus Calmette–Guérin containing sic gene in ex vivo and in vivo bladder cancer models | - |
dc.type | Article | - |
dc.identifier.doi | 10.4111/icu.20210425 | - |
dc.identifier.bibliographicCitation | Investigative and Clinical Urology, v.63, no.2, pp 228 - 237 | - |
dc.identifier.kciid | ART002818353 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000813508000014 | - |
dc.identifier.scopusid | 2-s2.0-85125882641 | - |
dc.citation.endPage | 237 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 228 | - |
dc.citation.title | Investigative and Clinical Urology | - |
dc.citation.volume | 63 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Antimicrobial peptide | - |
dc.subject.keywordAuthor | Bacillus Calmette–Guérin | - |
dc.subject.keywordAuthor | Bladder cancer | - |
dc.subject.keywordAuthor | Genetic recombination | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.